{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:23Z","timestamp":1788542003249,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Frunevetmab is a felinized anti-nerve growth factor monoclonal antibody that alleviates osteoarthritis (OA) pain in cats by blocking nerve growth factor (NGF) signaling. While its efficacy is established, comprehensive real-world safety profiles remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To analyze frunevetmab-associated adverse events (AEs) using real-world data from the United States Food and Drug Administration (FDA) Animal Drug Adverse Events (ADAE) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Adverse event reports submitted for cats receiving frunevetmab, extracted from the FDA ADAE database (January 2022 - December 2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality in frunevetmab-associated AEs was assessed by calculating the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence-propagation neural network, and the multi-item gamma Poisson shrinker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 33,378 feline AE reports, 5,248 frunevetmab-specific reports were analyzed. Frunevetmab-induced AEs spanned 24 system organ categories. Among the 19 significant preferred terms (PTs) identified, the most frequently reported AEs included pruritus, unspecified skin disorders, alopecia, dermatitis and eczema, and unspecified skin lesions. Notably, the AEs with the highest signal strength were skin ulceration, unspecified skin disorders, unspecified skin lesions, injection site pain, and dermatitis and eczema. In addition, unexpected significant AEs (e.g., abnormal cytology, arthritis, paresis) were detected, all of which were absent from the package insert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>We identified new potential AE signals for frunevetmab, emphasizing the need for robust clinical monitoring. Although these hypothesis-generating findings from disproportionality analysis require validation, they offer immediate, valuable guidance for veterinarians to optimize the safe use of this treatment in cats with OA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag003","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:48:11Z","timestamp":1770832091000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-7819","authenticated-orcid":false,"given":"Xiaoheng","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital of Xiamen Medical College , No. 566 Shengguang Street, Xiamen, Fujian 361024 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3247-6904","authenticated-orcid":false,"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital , No. 134 Dongjie Street, Fuzhou 350001, Fujian ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5065-6328","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital , Pingtan Comprehensive Experimental Area, Fuzhou, Fujian 350400 ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8548-0555","authenticated-orcid":false,"given":"Lifang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital of Xiamen Medical College , No. 566 Shengguang Street, Xiamen, Fujian 361024 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital , No. 134 Dongjie Street, Fuzhou, Fujian 350001 , PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2729","authenticated-orcid":false,"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital , Pingtan Comprehensive Experimental Area, Fuzhou, Fujian 350400 ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026021112480826100_ref1","doi-asserted-by":"publisher","first-page":"1098612x251347999","DOI":"10.1177\/1098612X251347999","article-title":"Osteoarthritis in cats: what we know, and mostly, what we don\u2019t know. . . Yet","volume":"27","author":"Lefort-Holguin","year":"2025","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.tvjl.2009.12.014","article-title":"Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats","volume":"187","author":"Slingerland","year":"2011","journal-title":"Vet J"},{"key":"2026021112480826100_ref3","doi-asserted-by":"publisher","first-page":"1395360","DOI":"10.3389\/fvets.2024.1395360","article-title":"Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study","volume":"11","author":"Reid","year":"2024","journal-title":"Front Vet Sci"},{"key":"2026021112480826100_ref4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2460\/javma.252.5.565","article-title":"Evaluation of tramadol for treatment of osteoarthritis in geriatric cats","volume":"252","author":"Guedes","year":"2018","journal-title":"J Am Vet Med Assoc"},{"key":"2026021112480826100_ref5","doi-asserted-by":"publisher","first-page":"e0175565","DOI":"10.1371\/journal.pone.0175565","article-title":"Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis","volume":"12","author":"Monteiro","year":"2017","journal-title":"PLoS One"},{"key":"2026021112480826100_ref6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1098612X211066268","article-title":"2022 ISFM consensus guidelines on the management of acute pain in cats","volume":"24","author":"Steagall","year":"2022","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jsap.13566","article-title":"2022 WSAVA guidelines for the recognition, assessment and treatment of pain","volume":"64","author":"Monteiro","year":"2023","journal-title":"J Small Anim Pract"},{"key":"2026021112480826100_ref8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jfms.2007.10.007","article-title":"Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg\/kg for treatment of osteoarthritic pain in cats","volume":"10","author":"Gunew","year":"2008","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref9","doi-asserted-by":"publisher","first-page":"1098612x241241951","DOI":"10.1177\/1098612X241241951","article-title":"2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats","volume":"26","author":"Taylor","year":"2024","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","article-title":"Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?","volume":"74","author":"Bannwarth","year":"2014","journal-title":"Drugs"},{"key":"2026021112480826100_ref11","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/jvim.16291","article-title":"Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats","volume":"35","author":"Gruen","year":"2021","journal-title":"J Vet Intern Med"},{"key":"2026021112480826100_ref12","doi-asserted-by":"publisher","first-page":"610028","DOI":"10.3389\/fvets.2021.610028","article-title":"Efficacy and safety of an anti-nerve growth factor antibody (frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study","volume":"8","author":"Gruen","year":"2021","journal-title":"Front Vet Sci"},{"key":"2026021112480826100_ref13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5326\/JAAHA-MS-7292","article-title":"2022 AAHA pain management guidelines for dogs and cats","volume":"58","author":"Gruen","year":"2022","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026021112480826100_ref14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/vr.104590","article-title":"Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats","volume":"184","author":"Enomoto","year":"2019","journal-title":"Vet Rec"},{"key":"2026021112480826100_ref15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/papr.12342","article-title":"NGF\/TrkA Signaling as a therapeutic target for pain","volume":"16","author":"Hirose","year":"2016","journal-title":"Pain Pract"},{"key":"2026021112480826100_ref16","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2026021112480826100_ref17","author":"U.S. Food and Drug Administration"},{"key":"2026021112480826100_ref18","author":"U.S. Food and Drug Administration"},{"key":"2026021112480826100_ref19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in Pharmaco vigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2026021112480826100_ref20","volume-title":"Combined Veddra List of Clinical Terms for Reporting Suspected Adverse Events in Animals and Humans to Veterinary Medicinal Products","author":"European Medicines Agency CVMP","year":"2023"},{"key":"2026021112480826100_ref21","volume-title":"Guidance Notes on the Use of Veddra Terminology for Reporting Suspected Adverse Events in Animals and Humans","author":"European Medicines Agency CVMP","year":"2023"},{"key":"2026021112480826100_ref22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1098612X11432828","article-title":"Osteoarthritis in the cat","volume":"14","author":"Bennett","year":"2012","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/vr.157.25.793","article-title":"Prevalence of radiographic signs of degenerative joint disease in a hospital population of cats","volume":"157","author":"Clarke","year":"2005","journal-title":"Vet Rec"},{"key":"2026021112480826100_ref24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/annrheumdis-2013-204763","article-title":"The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026021112480826100_ref25","doi-asserted-by":"publisher","first-page":"1098612x231198416","DOI":"10.1177\/1098612X231198416","article-title":"Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections","volume":"25","author":"Storrer","year":"2023","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1638\/2023-0122","article-title":"Use of solensia (frunevetmab) in nondomestic felids (Panthera tigris, Lynx rufus, Panthera uncia) guided by protein sequence analysis","volume":"55","author":"Richard","year":"2024","journal-title":"J Zoo Wildl Med"},{"key":"2026021112480826100_ref27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/joneph\/20.2.186","article-title":"Nerve growth factor (NGF) and NGF-receptor expression in diseased human kidneys","volume":"20","author":"Bonofiglio","year":"2007","journal-title":"J Nephrol"},{"key":"2026021112480826100_ref28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/jvim.13972","article-title":"A feline-specific anti-nerve growth factor antibody improves mobility in cats with degenerative joint disease-associated pain: a pilot proof of concept study","volume":"30","author":"Gruen","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026021112480826100_ref29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1098612X13511446","article-title":"Prevalence and classification of chronic kidney disease in cats randomly selected from four age groups and in cats recruited for degenerative joint disease studies","volume":"16","author":"Marino","year":"2014","journal-title":"J Feline Med Surg"},{"key":"2026021112480826100_ref30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0006-8993(80)90341-8","article-title":"Effects of long-term nerve growth factor deprivation on the nervous system of the adult rat: an experimental autoimmune approach","volume":"198","author":"Gorin","year":"1980","journal-title":"Brain Res"},{"key":"2026021112480826100_ref31","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1523\/JNEUROSCI.10-07-02412.1990","article-title":"Nerve growth factor regulates sympathetic ganglion cell morphology and survival in the adult mouse","volume":"10","author":"Ruit","year":"1990","journal-title":"J Neurosci"},{"key":"2026021112480826100_ref32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0006-8993(75)90274-7","article-title":"A study of the de- and regenerative changes in the sympathetic nervous system of the adult mouse after treatment with the antiserum to nerve growth factor","volume":"92","author":"Bjerre","year":"1975","journal-title":"Brain Res"},{"key":"2026021112480826100_ref33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/toxsci\/kfx089","article-title":"From the cover: evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult Cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardiofunctional assessment","volume":"158","author":"Belanger","year":"2017","journal-title":"Toxicol Sci"},{"key":"2026021112480826100_ref34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.toxlet.2021.02.018","article-title":"Neurotoxicity studies with a tropomyosin-related kinase a inhibitor, ASP7962, on the sympathetic and sensory nervous systems in rats","volume":"344","author":"Kigami","year":"2021","journal-title":"Toxicol Lett"},{"key":"2026021112480826100_ref35","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"2026021112480826100_ref36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/jnc.12093","article-title":"Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management","volume":"124","author":"McKelvey","year":"2013","journal-title":"J Neurochem"},{"key":"2026021112480826100_ref37","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fvets.2025.1628681","article-title":"Commentary: musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Brunke","year":"2025","journal-title":"Front Vet Sci"},{"key":"2026021112480826100_ref38","doi-asserted-by":"publisher","first-page":"1581490","DOI":"10.3389\/fvets.2025.1581490","article-title":"Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Farrell","year":"2025","journal-title":"Front Vet Sci"},{"key":"2026021112480826100_ref39","author":"U.S. Food and Drug Administration"},{"key":"2026021112480826100_ref40","doi-asserted-by":"publisher","first-page":"1558222","DOI":"10.3389\/fvets.2025.1558222","article-title":"Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela\u2122)","volume":"12","author":"Monteiro","year":"2025","journal-title":"Front Vet Sci"},{"key":"2026021112480826100_ref41","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"2026021112480826100_ref42","doi-asserted-by":"publisher","first-page":"e0126413","DOI":"10.1371\/journal.pone.0126413","article-title":"Bias in spontaneous reporting of adverse drug reactions in Japan","volume":"10","author":"Matsuda","year":"2015","journal-title":"PLoS One"},{"key":"2026021112480826100_ref43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"2026021112480826100_ref44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","article-title":"Trends of reporting of \u201cserious\u201d vs. \u201cnon-serious\u201d adverse drug reactions over time: a study in the French Pharmaco vigilance database","volume":"74","author":"Moulis","year":"2012","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalag003\/66852211\/aalag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalag003\/66852211\/aalag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:48:13Z","timestamp":1770832093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag003\/8472806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag003","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"aalag003"}}